Bioscience Animal Health PCL (BKK:BIS)
Thailand · Delayed Price · Currency is THB 2.100
+0.060 (2.94%)
May 29, 2026, 4:25 PM ICT
BKK:BIS Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,201 | 2,254 | 2,324 | 2,412 | 2,194 | 1,975 |
Other Revenue | 7.57 | - | - | - | 18.86 | 11.48 |
| 2,208 | 2,254 | 2,324 | 2,412 | 2,213 | 1,986 | |
Revenue Growth (YoY) | -5.19% | -3.01% | -3.68% | 9.00% | 11.43% | 11.47% |
Cost of Revenue | 1,877 | 1,912 | 1,978 | 2,080 | 1,877 | 1,628 |
Gross Profit | 330.89 | 342.14 | 345.75 | 332.8 | 335.81 | 358.34 |
Selling, General & Admin | 311.99 | 322.28 | 291.02 | 279.03 | 260.17 | 262.37 |
Other Operating Expenses | -36.31 | -36.39 | -40.11 | -14.52 | - | - |
Operating Expenses | 275.68 | 285.89 | 250.91 | 264.51 | 260.17 | 262.37 |
Operating Income | 55.21 | 56.25 | 94.84 | 68.29 | 75.63 | 95.97 |
Interest Expense | -0.7 | -1.2 | -2.63 | -1.89 | -6.27 | -9.94 |
Earnings From Equity Investments | - | - | - | - | - | 0.3 |
EBT Excluding Unusual Items | 54.51 | 55.05 | 92.21 | 66.4 | 69.37 | 86.33 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.27 |
Gain (Loss) on Sale of Assets | - | - | - | - | 6.4 | - |
Pretax Income | 54.51 | 55.05 | 92.21 | 66.4 | 75.77 | 86.6 |
Income Tax Expense | 11.92 | 12.29 | 20.55 | 13.52 | 16.09 | 17.97 |
Earnings From Continuing Operations | 42.59 | 42.76 | 71.66 | 52.88 | 59.67 | 68.62 |
Minority Interest in Earnings | -5.21 | -4.29 | -6.62 | -2.18 | -3.76 | 3.78 |
Net Income | 37.38 | 38.47 | 65.04 | 50.71 | 55.92 | 72.4 |
Net Income to Common | 37.38 | 38.47 | 65.04 | 50.71 | 55.92 | 72.4 |
Net Income Growth | -46.74% | -40.85% | 28.27% | -9.32% | -22.77% | 16.34% |
Shares Outstanding (Basic) | 313 | 314 | 314 | 314 | 284 | 220 |
Shares Outstanding (Diluted) | 313 | 314 | 314 | 314 | 284 | 220 |
Shares Change (YoY) | -0.20% | - | - | 10.71% | 28.91% | 25.24% |
EPS (Basic) | 0.12 | 0.12 | 0.21 | 0.16 | 0.20 | 0.33 |
EPS (Diluted) | 0.12 | 0.12 | 0.21 | 0.16 | 0.20 | 0.33 |
EPS Growth | -46.63% | -40.85% | 28.27% | -18.09% | -40.09% | -7.11% |
Free Cash Flow | 223.38 | 274.09 | 98.5 | -28.66 | -47.25 | 18.49 |
Free Cash Flow Per Share | 0.71 | 0.87 | 0.31 | -0.09 | -0.17 | 0.08 |
Dividend Per Share | - | 0.120 | 0.140 | 0.110 | 0.122 | 0.410 |
Dividend Growth | - | -14.29% | 27.27% | -10.20% | -70.12% | 198.18% |
Gross Margin | 14.99% | 15.18% | 14.88% | 13.79% | 15.17% | 18.04% |
Operating Margin | 2.50% | 2.50% | 4.08% | 2.83% | 3.42% | 4.83% |
Profit Margin | 1.69% | 1.71% | 2.80% | 2.10% | 2.53% | 3.65% |
Free Cash Flow Margin | 10.12% | 12.16% | 4.24% | -1.19% | -2.14% | 0.93% |
EBITDA | 69.25 | 72 | 110.01 | 80.56 | 87.92 | 108.41 |
EBITDA Margin | 3.14% | 3.19% | 4.73% | 3.34% | 3.97% | 5.46% |
D&A For EBITDA | 14.03 | 15.75 | 15.17 | 12.27 | 12.29 | 12.44 |
EBIT | 55.21 | 56.25 | 94.84 | 68.29 | 75.63 | 95.97 |
EBIT Margin | 2.50% | 2.50% | 4.08% | 2.83% | 3.42% | 4.83% |
Effective Tax Rate | 21.87% | 22.33% | 22.29% | 20.36% | 21.24% | 20.75% |
Revenue as Reported | 2,262 | 2,307 | 2,374 | 2,427 | 2,220 | 1,987 |